Nomura K
Committee of brain tumor registry in Japan, National Cancer Center.
Gan No Rinsho. 1989 Sep;35(11):1219-25.
From the data in vol. 6 of Brain Tumor Registry in Japan, there were mainly analyzed the survival rates of malignant astrocytoma and glioblastoma patients related to extent of surgical removal and postoperative radiation. Total removal of the supratentorial astrocytoma in brain revealed 75.9% in 5-year survival rate, whereas supratentorial malignant astrocytomas and glioblastomas, 43.7% and 20.9% in 5-year survival rates, respectively. Survival rates related to combination of operation and radiation therapy for the glioblastoma and malignant astrocytoma patients were analyzed according to the mode of operation. For glioblastomas, patients treated with biopsy and post-operative radiation therapy indicated higher survival rate of 6.3% in 5-year survival than the patients with biopsy and no radiation, 3.0% of 5-year survival rates (P less than 0.01 by Chi-square test). On the other hand, patients treated with 95%-100% removal by operation with or without radiation therapy showed 67.2% (with), 32.1% (without) in 1 year survival; 37.2%, 23.1% in 2 year survival; 27.1%, 20.0% in 3 year survival; 22.5%, 20.2% in 4 year survival and 20.4% and 19.4% in 5-year survival rates, respectively (P less than 0.05 by Chi-square test). Tentative TNM classification proposed by Japan to UICC was also discussed briefly.
根据日本脑肿瘤登记处第6卷中的数据，主要分析了恶性星形细胞瘤和胶质母细胞瘤患者的生存率与手术切除范围及术后放疗的关系。幕上星形细胞瘤全切除术后5年生存率为75.9%，而幕上恶性星形细胞瘤和胶质母细胞瘤的5年生存率分别为43.7%和20.9%。根据手术方式分析了胶质母细胞瘤和恶性星形细胞瘤患者手术与放疗联合治疗的生存率。对于胶质母细胞瘤，接受活检及术后放疗的患者5年生存率为6.3%，高于接受活检但未放疗的患者，后者5年生存率为3.0%（卡方检验P<0.01）。另一方面，手术切除95%-100%的患者，无论是否接受放疗，1年生存率分别为67.2%（接受放疗）、32.1%（未接受放疗）；2年生存率分别为37.2%、23.1%；3年生存率分别为27.1%、20.0%；4年生存率分别为22.5%、20.2%；5年生存率分别为20.4%、19.4%（卡方检验P<0.05）。还简要讨论了日本向国际抗癌联盟（UICC）提出的暂定TNM分类。
